Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 516

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

Open access
Hillengass, Jens, Usmani, Saad, Rajkumar, S Vincent, Durie, Brian G M, Mateos, María-Victoria, Lonial, Sagar, Joao, Cristina, Anderson, Kenneth C, García-Sanz, Ramón, Riva, Eloísa, Du, Juan, van de Donk, Niels, Berdeja, Jesús G, Terpos, Evangelos, Zamagni, Elena, Kyle, Robert A, San Miguel, Jesús, Goldschmidt, Hartmut, Giralt, Sergio, Kumar, Shaji, Raje, Noopur, Ludwig, Heinz, Ocio, Enrique, Schots, Rik, Einsele, Hermann, Schjesvold, Fredrik, Chen, Wen-Ming, Abildgaard, Niels, Lipe, Brea C, Dytfeld, Dominik, Wirk, Baldeep Mona, Drake, Matthew, Cavo, Michele, Lahuerta, Juan José, Lentzsch, Suzanne·2019·The Lancet Oncology
DOI 10.1016/s1470-2045(19)30309-2
Open this paper in CoChat — free account

Abstract

Recent advances in the treatment of multiple myeloma have increased the need for accurate diagnosis of the disease. The detection of bone and bone marrow lesions is crucial in the investigation of multiple myeloma and often dictates the decision to start treatment. Furthermore, detection of minimal residual disease is important for prognosis determination and treatment planning, and it has underscored an unmet need for sensitive imaging methods that accurately assess patient response to multiple myeloma treatment. Low-dose whole-body CT has increased sensitivity compared with conventional skeletal survey in the detection of bone disease, which can reveal information leading to changes in therapy and disease management that could prevent or delay the onset of clinically significant morbidity and mortality as a result of skeletal-related events. Given the multiple options available for the detection of bone and bone marrow lesions, ranging from conventional skeletal survey to whole-body CT, PET/CT, and MRI, the International Myeloma Working Group decided to establish guidelines on optimal use of imaging methods at different disease stages. These recommendations on imaging within and outside of clinical trials will help standardise imaging for monoclonal plasma cell disorders worldwide to allow the comparison of results and the unification of treatment approaches for multiple myeloma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(19)30309-2

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 49

  1. Ludwig, 2014, International Myeloma Working Group recommendations for global myeloma care, Leukemia, 28, 981, 10.1038/leu.2013.293 · DOI · Paper page
  2. Hillengass, 2013, Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: imaging “early myeloma”, Leuk Lymphoma, 54, 1355, 10.3109/10428194.2012.740559 · DOI
  3. Messiou, 2019, Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS), Radiology, 291, 5, 10.1148/radiol.2019181949 · DOI · Paper page
  4. Moulopoulos, 2018, Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group, Blood Cancer J, 8, 95, 10.1038/s41408-018-0124-1 · DOI
  5. Dimopoulos, 2009, International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma, Leukemia, 23, 1545, 10.1038/leu.2009.89 · DOI · Paper page
  6. 2003, Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group, Br J Haematol, 121, 749, 10.1046/j.1365-2141.2003.04355.x · DOI · Paper page
  7. Edelstyn, 1967, The radiological demonstration of osseous metastases. Experimental observations, Clin Radiol, 18, 158, 10.1016/S0009-9260(67)80010-2 · doi:10.1016/s0009-9260(67)80010-2
  8. Hillengass, 2016, Findings of whole body computed tomography compared to conventional skeletal survey in patients with monoclonal plasma cell disorders — a study of the International Myeloma Working Group, Blood, 128, 4468, 10.1182/blood.V128.22.4468.4468 · doi:10.1182/blood.v128.22.4468.4468
  9. Hinge, 2016, Baseline bone involvement in multiple myeloma — a prospective comparison of conventional X-ray, low-dose computed tomography, and 18fluorodeoxyglucose positron emission tomography in previously untreated patients, Haematologica, 101, e415, 10.3324/haematol.2016.146092 · DOI
  10. Kröpil, 2008, Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma, Eur Radiol, 18, 51, 10.1007/s00330-007-0738-3 · doi:10.1007/s00330-007-0738-3
  11. Wolf, 2014, Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease, Eur J Radiol, 83, 1222, 10.1016/j.ejrad.2014.02.008 · doi:10.1016/j.ejrad.2014.02.008
  12. Nishida, 2015, Clinical and prognostic significance of bone marrow abnormalities in the appendicular skeleton detected by low-dose whole-body multidetector computed tomography in patients with multiple myeloma, Blood Cancer J, 5, e329, 10.1038/bcj.2015.57 · DOI
  13. Horger, 2007, The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma, Cancer, 109, 1617, 10.1002/cncr.22572 · doi:10.1002/cncr.22572
  14. Horger, 2005, Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography, Eur J Radiol, 54, 289, 10.1016/j.ejrad.2004.04.015 · doi:10.1016/j.ejrad.2004.04.015
  15. Ippolito, 2013, Diagnostic value of whole-body low-dose computed tomography (WBLDCT) in bone lesions detection in patients with multiple myeloma (MM), Eur J Radiol, 82, 2322, 10.1016/j.ejrad.2013.08.036 · DOI
  16. Cretti, 2016, Patient dose evaluation for the whole-body low-dose multidetector CT (WBLDMDCT) skeleton study in multiple myeloma (MM), Radiol Med, 121, 93, 10.1007/s11547-015-0573-6 · doi:10.1007/s11547-015-0573-6
  17. Hillengass, 2016, Comparison of plasma cell infiltration in random samples of the bone marrow and osteolyses acquired by CT-guided biopsy in patients with symptomatic multiple myeloma, Proc Am Soc Clin Oncol, 34
  18. Grobner, 2006, Gadolinium — a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?, Nephrol Dial Transplant, 21, 1104, 10.1093/ndt/gfk062 · DOI · Paper page
  19. Zamagni, 2007, A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma, Haematologica, 92, 50, 10.3324/haematol.10554 · DOI · Paper page
  20. Koh, 2007, Diffusion-weighted MRI in the body: applications and challenges in oncology, AJR Am J Roentgenol, 188, 1622, 10.2214/AJR.06.1403 · DOI · Paper page
  21. Sachpekidis, 2015, Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma, Am J Nucl Med Mol Imaging, 5, 469
  22. Caserta, 2018, Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma, Blood, 131, 741, 10.1182/blood-2017-09-807263 · DOI
  23. Hillengass, 2014, Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance, Leukemia, 28, 174, 10.1038/leu.2013.244 · DOI
  24. Bhutani, 2016, Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging, Leuk Lymphoma, 57, 1114, 10.3109/10428194.2015.1090572 · DOI
  25. Minarik, 2016, Prospective comparison of conventional radiography, low-dose computed tomography and magnetic resonance imaging in monoclonal gammopathies, Biomed Pap Med Fac Univ Palacky Olomouc Czechoslov, 160, 305, 10.5507/bp.2015.064 · doi:10.5507/bp.2015.064
  26. Yuh, 1989, Vertebral compression fractures: distinction between benign and malignant causes with MR imaging, Radiology, 172, 215, 10.1148/radiology.172.1.2740506 · doi:10.1148/radiology.172.1.2740506
  27. Baker, 1990, Benign versus pathologic compression fractures of vertebral bodies: assessment with conventional spin-echo, chemical-shift, and STIR MR imaging, Radiology, 174, 495, 10.1148/radiology.174.2.2296658 · doi:10.1148/radiology.174.2.2296658
  28. Baur, 1998, Diffusion-weighted MR imaging of bone marrow: differentiation of benign versus pathologic compression fractures, Radiology, 207, 349, 10.1148/radiology.207.2.9577479 · DOI · Paper page
  29. Nahi, 2017, Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish myeloma register, Eur J Haematol, 99, 216, 10.1111/ejh.12907 · DOI
  30. Paiva, 2014, Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma, Blood, 124, 1300, 10.1182/blood-2014-04-567909 · DOI
  31. Kastritis, 2014, The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma, Leukemia, 28, 2402, 10.1038/leu.2014.230 · DOI
  32. Hillengass, 2010, Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma, J Clin Oncol, 28, 1606, 10.1200/JCO.2009.25.5356 · DOI · Paper page
  33. Zamagni, 2016, 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease, Leukemia, 30, 417, 10.1038/leu.2015.291 · DOI
  34. Siontis, 2015, Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy, Blood Cancer J, 5, e364, 10.1038/bcj.2015.87 · DOI
  35. Merz, 2014, Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma, Leukemia, 28, 1902, 10.1038/leu.2014.75 · DOI
  36. Bartel, 2009, F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma, Blood, 114, 2068, 10.1182/blood-2009-03-213280 · DOI · Paper page
  37. Walker, 2007, Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications, J Clin Oncol, 25, 1121, 10.1200/JCO.2006.08.5803 · DOI · Paper page
  38. Usmani, 2013, Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3, Blood, 121, 1819, 10.1182/blood-2012-08-451690 · DOI · Paper page
  39. Davies, 2018, Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma, Haematologica, 103, 1047, 10.3324/haematol.2017.177139 · DOI
  40. Zamagni, 2011, Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation, Blood, 118, 5989, 10.1182/blood-2011-06-361386 · DOI · Paper page
  41. Zamagni, 2015, PET/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma, Clin Cancer Res, 21, 4384, 10.1158/1078-0432.CCR-15-0396 · DOI · Paper page
  42. Moreau, 2017, J Clin Oncol, 35, 2911, 10.1200/JCO.2017.72.2975 · DOI · Paper page
  43. Hillengass, 2012, Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma, Haematologica, 97, 1757, 10.3324/haematol.2012.065359 · DOI
  44. Pawlyn, 2016, Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?, Leukemia, 30, 1446, 10.1038/leu.2015.338 · DOI
  45. Rasche, 2017, Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma, Blood, 130, 30, 10.1182/blood-2017-03-774422 · DOI · Paper page
  46. Rasche, 2018, Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma, Leukemia
  47. Spinnato, 2012, Contrast enhanced MRI and 18F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease, Eur J Radiol, 81, 4013, 10.1016/j.ejrad.2012.06.028 · DOI
  48. Bäuerle, 2009, Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging, Radiology, 252, 477, 10.1148/radiol.2522081756 · DOI
  49. Cavo, 2017, Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group, Lancet Oncol, 18, e206, 10.1016/S1470-2045(17)30189-4 · DOI · Paper page

Cited by

See all 516

Metadata

Authors
Hillengass, J., Usmani, S., Rajkumar, S. V., Durie, B. G. M., Mateos, M.-V., Lonial, S., Joao, C., Anderson, K. C., García-Sanz, R., Riva, E., Du, J., van de Donk, N., Berdeja, J. G., Terpos, E., Zamagni, E., Kyle, R. A., San Miguel, J., Goldschmidt, H., Giralt, S., Kumar, S., Raje, N., Ludwig, H., Ocio, E., Schots, R., Einsele, H., Schjesvold, F., Chen, W.-M., Abildgaard, N., Lipe, B. C., Dytfeld, D., Wirk, B. M., Drake, M., Cavo, M., Lahuerta, J. J., & Lentzsch, S.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2019-06
Volume
20
Issue
6
Pages
e302-e312
ISSN
1470-2045 (ISSN-L)
DOI
10.1016/s1470-2045(19)30309-2
OpenAlex
W2947708728
Cited by
516
References
8
FWCI
36.11
Type
journal article
Language
en
Update notices
erratum (2019-07-01)
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. https://app.cochat.ai/papers/10.1016/s1470-2045(19)30309-2
The paper
Hillengass, J., Usmani, S., Rajkumar, S. V., Durie, B. G. M., Mateos, M.-V., Lonial, S., Joao, C., Anderson, K. C., García-Sanz, R., Riva, E., Du, J., van de Donk, N., Berdeja, J. G., Terpos, E., Zamagni, E., Kyle, R. A., San Miguel, J., Goldschmidt, H., Giralt, S., . . . Lentzsch, S. (2019). International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(19)30309-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.